Hypoparathyroidism Therapies
Hypoparathyroidism Market

Hypoparathyroidism 


Hypoparathyroidism is characterized by hypocalcemia and hyperphosphatemia due to a lack of parathyroid hormone (PTH) secretion or action. Hypoparathyroidism may occur as part of a pluriglandular autoimmune disorder or as a complex congenital defect, for example in the autosomal dominant DiGeorge or hypoparathyroidism, deafness, and renal dysplasia (HDR) syndromes.


Hypoparathyroidism Epidemiology Segmentation in the 7MM


  • Prevalent Cases of Hypoparathyroidism
  • Diagnosed Prevalent Cases of Hypoparathyroidism
  • Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism
  • Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism
  • Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism
  • Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism


Hypoparathyroidism Epidemiological Insights Observed in the 7MM (2021)


  • The total prevalent population of Hypoparathyroidism in the 7MM was found to be 280k.
  • The total prevalent population of Hypoparathyroidism in the UK are estimated to be 34.5k.
  • The total prevalent population of Hypoparathyroidism in Japan are found to be 22.3k.


Hypoparathyroidism Market Insight


The market size of Hypoparathyroidism in the 7MM was found to be USD 235 million in 2021.  


Hypoparathyroidism Market Drivers


  • Rising prevalence of neck surgeries and autoimmune diseases
  • Rising awareness
  • Presence of major players


Hypoparathyroidism Market Barriers


  • Knowledge gap
  • Poor quality of life
  • Availability of generics and off-label therapies


Hypoparathyroidism Emerging Therapies


The emerging drugs  in the Hypoparathyroidism market are


  • TransCon PTH
  • EB612
  • Encaleret (BBP-305/CLTX-305), and many others


Hypoparathyroidism Key Players 


The key players working in the Hypoparathyroidism market are


  • Ascendis Pharma
  • EnteraBio
  • Bridgebio
  • Calcilytix Therapeutics, and many others